推動精準醫療，改善治療品質，帶來幸福與希望 Advancing Precision Medicine. Enhancing Lives. Delivering Hope and Happiness.
我們擁有一系列專有的連結分子庫 We possess a proprietary library of diverse linker molecules.
更具備多種核醫放射藥物之開發經驗Extensive experience in the development of diverse radiopharmaceuticals.
透過授權合作夥伴推動全球市場拓展Expanding Global Reach through Strategic Partnerships.
1Chi-Wei Chang,1 Hsin-En Tsai, 2Ching-Huang Lo, 1Ya-Yao Huang* 1 Primo Biotechnology Co., Ltd., Taipei, Taiwan 2 Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan. This study reports on the GMP-compliant process for the preparation of [18F]PSMA-1007 using a Neptis RS…
Prostate cancer is one of the most common malignant tumors among men and has ranked among the leading cancers in Taiwan in recent years. With an aging population and increasing awareness of early detection, achieving accurate diagnosis at an early stage has become a critical challenge for clinicians and the medical community. Against this backdrop,…
Dr. Ya-Yao Huang, CEO of Primo Biotechnology, was invited to deliver a keynote lecture at the American Association for Cancer Research (AACR), one of the world’s leading organizations dedicated to cancer research. Lecture Topic: Molecular Imaging: Update on PET Imaging in Oncological Research Dr. Huang will share innovative developments in radiopharmaceuticals and their clinical applications,…
Primo has long been dedicated to advancing the field of nuclear medicine, constantly pushing the boundaries of innovation and quality. This year, we are proud to take the stage at the 2025 Annual Conference of Society of Nuclear Medicine, where our latest research has been officially recognized and featured—marking another milestone in our journey of…
Primo Biotech announced today a significant advancement in the development of PB-012, its proprietary radiotracer focusing on angiogenesis. The company has successfully completed the First Patient In (FPI) for the Phase I clinical trial at a medical center in Kaohsiung. This clinical trial aims to evaluate the diagnostic efficacy and safety of PB-012 in patients…
According to Taiwan’s National Health Insurance data, 9,858 new cases of prostate cancer and 1,897 related deaths were recorded in 2024, making it the third most common cancer among men and the fastest-growing malignancy in recent years. Prof. Yen-Chuan Ou, Superintendent of the Research and Innovation Center at Tung’s Taichung MetroHarbor Hospital, emphasized that the…
Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development. The two companies will jointly develop and manufacture an innovative peptide-based radioligand therapeutic, targeting solid tumors diagnosis and treatment —…
Primo Biotechnology Co., Ltd., a pioneering developer of radiopharmaceuticals, today announced a strategic partnership with Terthera B.V., a radionuclide production-focused company based in The Netherlands. Under the agreement, Terthera will supply Primo with high-purity, non-carrier-added (NCA), GMP-grade Terbium-161 (Tb-161), a next-generation therapeutic radionuclide. Primo has also secured exclusive distribution rights for Tb-161 in Taiwan. This…
1Huang Ya-Ting, 1Chen Li-Yu, 2Chang Yen-Hsiang. 1 Primo Biotechnology Co., Ltd , Taipei, Taiwan. 2Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan. This study poster was presented at 2025 65th Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM). Purpose: To evaluate the clinical benefit of Radium-223 (Ra-223) in delaying symptomatic skeletal…
1Chen Li-Yu, 1Huang Ya-Ting ,2Fan Yu-Ming. 1 Primo Biotechnology Co., Ltd , Taipei, Taiwan. 2Department of Nuclear Medicine, Cardinal Tien Hospital, New Taipei City, Taiwan.. This study poster was presented at 2025 65th Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM). Purpose: To assess the cost-utility of 18F-fluorodeoxyglucose (FDG) imaging versus other diagnostic…
我們一直在尋求創新的藥物合作夥伴關係，完美的將您的專業領域與我們領先的放射性同位素平台技術融合起來，開發下一代診斷和治療藥物，幫助對抗嚴重且難以治療的癌症疾病。
We are constantly seeking innovative drug partnerships that synergize your expertise with our leading radioisotope technology. Together, we develop next-generation diagnostics and therapeutics to combat severe and hard-to-treat cancers.
